AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the United States. Revenue climbed 12 percent to ...

AstraZeneca raised its prediction for 2010 core EPS by 30 cents to $6.35 (4.07 pounds) to $6.65 (4.26 pounds), against 2009's $6.32 (4.05 pounds), helping drive a 4 percent rise in the shares by ...

AstraZeneca plc AZN was saved from heartache after its heart disease drug Brilinta succeeded in a late-stage study, sending its shares higher Monday. AstraZeneca said the Phase 3 study dubbed ...

AstraZeneca <AZN.L> doubled its 2010 share buyback programme on Thursday, after posting strong results and winning an endorsement from a U.S. advisory panel for its potential blockbuster ...